In an exciting development for diabetes patients, trailblazing biotech company Hua Medicine is preparing to start a clinical trial in the United States for its global first-in-class diabetes drug dorzagliatin. The US FDA accepted Hua Medicine’s IND application for the second-generation dorzagliatin at the end of 2023, a significant step towards global access to an innovative drug that is currently only available in mainland China.
As Hua Medicine gears up to launch a trial in Q2, the story of dorzagliatin and the minds behind its development are an incredible story for your audience and a powerful counterpoint to the global captivation with the weight-loss impacts of GLP-1 drugs – drugs that also help manage the symptoms of diabetes but with significant side-effects.
Dorzagliatin is a first-in-class allosteric glucokinase activator designed to address the root causes of diabetes—a significant leap from the traditional approach of merely managing symptoms. The efficacy and uniqueness of this new drug have been thoroughly documented and are a game-changer for millions worldwide, heralding a new dawn in diabetes care thanks to the potential for remission and the chance of living drug-free that dorzagliatin represents, without any of the debilitating side effects.
Hua Medicine’s CEO Dr Chen Li, is at the forefront of innovative research into diabetes, leading a company that is revolutionizing how the world confronts this significant and often overlooked global health challenge.
Dr Chen’s storied career has been defined by an unrelenting dedication to battling diabetes. Under his leadership, Hua Medicine has developed dorzagliatin and grown into a beacon of innovation. An interview with Dr Chen will provide you with a detailed perspective on the drug's inception and development, the technology behind it, and the future of diabetes treatment.
We would like to offer you the unique opportunity to interview Dr Chen, providing your readers with insider insights into these ground-breaking developments and why dorzagliatin represents such a significant step forward in treating diabetes and even achieving remission, freeing patients from the shackles of daily drug management or insulin injections.
Should this opportunity interest you, please contact us to arrange an interview with Dr. Chen.
